Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Cronin, W. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogel, V. G.
Right arrow Articles by Cronin, W. M.
Clinical Cancer Research Vol. 9, 495S-501s, January 2003
© 2003 American Association for Cancer Research

Supplement

National Surgical Adjuvant Breast and Bowel Project Update

Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ1

Victor G. Vogel2, Joseph P. Costantino, D. Lawrence Wickerham and Walter M. Cronin

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213-3180 [V. G. K.] and the NSABP Foundation, Inc., Pittsburgh, Pennsylvania 15212-5234 [J. P. C., D. L. W., W. M. C.]

Following up on the results of recent completed trials, several major breast cancer prevention trials are either underway or impending. In the Study of Tamoxifen and Raloxifene trial, eligible women are at least 35 years of age and postmenopausal, with either lobular carcinoma in situ or a 5-year risk of invasive breast cancer of at least 1.67%. The study will compare the ability of 5 years of tamoxifen or raloxifene to reduce the incidence of breast cancer. Subjects are randomly assigned to receive either 20 mg of tamoxifen or 60 mg of raloxifene daily. After 3 years of recruitment, 13,647 women have been randomized (20.7% of those eligible). The median age of randomized women is 58 years (mean age, 58 years), and their median 5-year risk of breast cancer is 3.3% (mean 5-year risk of breast cancer, 4.0%). Hysterectomy was reported by 52.5% of the randomized women; lobular carcinoma in situ was reported by 8.4% of subjects before randomization. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial, 1,804 women with ductal carcinoma in situ were randomly assigned tamoxifen after lumpectomy and radiation therapy. Women in the tamoxifen group had fewer breast cancer events at 5 years than did those on placebo (8.2% versus 13.4%, P = 0.0009). The proposed NSABP B-35 trial will have the same design as NSABP B-24 but will compare tamoxifen with anastrozole in postmenopausal women. Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003.




This article has been cited by other articles:


Home page
 JCOHome page
T. W.F. Yen, H. M. Kuerer, R. A. Ottesen, L. Rouse, J. C. Niland, S. B. Edge, R. L. Theriault, and J. C. Weeks
Impact of Randomized Clinical Trial Results in the National Comprehensive Cancer Network on the Use of Tamoxifen After Breast Surgery for Ductal Carcinoma in Situ
J. Clin. Oncol., August 1, 2007; 25(22): 3251 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
V. G. Vogel, J. P. Costantino, D. L. Wickerham, W. M. Cronin, R. S. Cecchini, J. N. Atkins, T. B. Bevers, L. Fehrenbacher, E. R. Pajon Jr, J. L. Wade III, et al.
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
JAMA, June 21, 2006; 295(23): 2727 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
B. K. Dunn
Hormonal Interventions: From Adjuvant Therapy to Breast Cancer Prevention
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 185 - 188.
[Full Text] [PDF]

Home page
 JCOHome page
B. K. Dunn, D. L. Wickerham, and L. G. Ford
Prevention of Hormone-Related Cancers: Breast Cancer
J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Martino, J. A. Cauley, E. Barrett-Connor, T. J. Powles, J. Mershon, D. Disch, R. J. Secrest, S. R. Cummings, and For the CORE Investigators
Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
J Natl Cancer Inst, December 1, 2004; 96(23): 1751 - 1761.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Martino, J. Costantino, M. McNabb, J. Mershon, K. Bryant, T. Powles, and R. J. Secrest
The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials
Oncologist, April 1, 2004; 9(2): 116 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Frasor, F. Stossi, J. M. Danes, B. Komm, C. R. Lyttle, and B. S. Katzenellenbogen
Selective Estrogen Receptor Modulators: Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells
Cancer Res., February 15, 2004; 64(4): 1522 - 1533.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.